These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33549676)

  • 1. All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis.
    Rados DV; Falcetta MRR; Pinto LC; Leitão CB; Gross JL
    Diabetes Res Clin Pract; 2021 Mar; 173():108688. PubMed ID: 33549676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
    Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials.
    Li J; Tong Y; Zhang Y; Tang L; Lv Q; Zhang F; Hu R; Tong N
    Clin Ther; 2016 Feb; 38(2):372-386.e6. PubMed ID: 26774276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for coronary artery disease in patients with type 2 diabetes: a meta-analysis and trial sequential analysis.
    Rados DV; Pinto LC; Leitão CB; Gross JL
    BMJ Open; 2017 May; 7(5):e015089. PubMed ID: 28490559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials.
    Varvaki Rados D; Catani Pinto L; Reck Remonti L; Bauermann Leitão C; Gross JL
    PLoS Med; 2016 Apr; 13(4):e1001992. PubMed ID: 27071029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials.
    Erpeldinger S; Rehman MB; Berkhout C; Pigache C; Zerbib Y; Regnault F; Guérin E; Supper I; Cornu C; Kassaï B; Gueyffier F; Boussageon R
    BMC Endocr Disord; 2016 Jul; 16(1):39. PubMed ID: 27391319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review.
    Price HI; Agnew MD; Gamble JM
    BMJ Open; 2015 Mar; 5(3):e006341. PubMed ID: 25762229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2011 Jun; (6):CD008143. PubMed ID: 21678374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
    Bain S; Druyts E; Balijepalli C; Baxter CA; Currie CJ; Das R; Donnelly R; Khunti K; Langerman H; Leigh P; Siliman G; Thorlund K; Toor K; Vora J; Mills EJ
    Diabetes Obes Metab; 2017 Mar; 19(3):329-335. PubMed ID: 27862902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.
    Rådholm K; Wu JH; Wong MG; Foote C; Fulcher G; Mahaffey KW; Perkovic V; Neal B
    Diabetes Res Clin Pract; 2018 Jun; 140():118-128. PubMed ID: 29604389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.
    Boussageon R; Supper I; Bejan-Angoulvant T; Kellou N; Cucherat M; Boissel JP; Kassai B; Moreau A; Gueyffier F; Cornu C
    PLoS Med; 2012; 9(4):e1001204. PubMed ID: 22509138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive glucose control in diabetics with an acute myocardial infarction does not improve mortality and increases risk of hypoglycemia-a meta-regression analysis.
    Chatterjee S; Sharma A; Lichstein E; Mukherjee D
    Curr Vasc Pharmacol; 2013 Jan; 11(1):100-4. PubMed ID: 22724474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different insulin types and regimens for pregnant women with pre-existing diabetes.
    O'Neill SM; Kenny LC; Khashan AS; West HM; Smyth RM; Kearney PM
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD011880. PubMed ID: 28156005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.